Pages: 1 ... 6 7 8 9 [10]
91
« Last post by BurnMan on April 28, 2024, 07:01:38 PM »
92
« Last post by jones on April 23, 2024, 09:17:45 PM »
C'mon man, everyone knows the election for President is between a shit sandwich and a giant douche
Only a dummy would run for President, or someone desperate to stay outta jail...
Or maybe both!
Biden is giving hundreds of billions to people too dumb to pay for their own college--That's obviously for buying their votes. Why should my tax dollars be paying for that? I never graduated college, why the f**k should my taxes be paying for someone who did?
93
« Last post by JustSayin on April 23, 2024, 05:51:27 PM »
When is the last time a Vice President had more than a slight impact on US politics? Mike Pence would have if they had either needed to cut him down from a noose or he delivered the false electoral votes... scary how close either of those scenarios came to fruition. Our current electorate politicians exist only to gain power, money or fame. I wish the unicorn politicians that exist in the lower levels of government and actually give a damn could make it to Washington. This is our House of representatives  
94
« Last post by BurnMan on April 23, 2024, 01:35:44 PM »
Gaslighting is the term. 
95
« Last post by 3V1L9371U5 on April 23, 2024, 01:33:21 PM »
Don't believe the hype. I still remember her standing on stage in 2020 squeaking "...b-b-but we'll legalize marijuana!" as people were already headed for the door. Since that time, this party has been in a state of power that is nearly unchecked and historical in scope... but somehow they just haven't got around to it yet. Amazing how it's come up as a topic of conversation again, isn't it? *Stares accusingly at election calendar* Kind of like how whenever Dems or Reps (one side really is as bad as the other, here) gain control of all 3 branches, yet fail to enact their supposed agenda. Why? Because that was never the damn plan in the first place. ...and I suppose that we should be happy for that, otherwise we'd all be living in an alternate left/right wing hellscape that's even worse than what we've got. A lilttle bit of goddamn integrity in politics would be a refreshing change, though. Too bad we'll never find out what that's like... 
96
« Last post by 1954 on April 21, 2024, 08:01:05 PM »
Happy 420. 
97
« Last post by BurnMan on April 20, 2024, 02:11:46 PM »
98
« Last post by orthene on April 18, 2024, 11:42:06 PM »
https://abcnews.go.com/Business/wireStory/kentucky-governor-announces-lottery-award-initial-round-medical-109402560FRANKFORT, Ky. -- Kentucky will use a lottery system to award an initial round of licenses to businesses competing to participate in the state's startup medical cannabis program, Gov. Andy Beshear announced Thursday.
The governor called it a fair way to give each applicant that clears the screening process an opportunity to land a license for the program, which launches statewide at the start of 2025.
The lottery, set for October, should remove any temptation to lobby in an effort to “get a leg up in different ways that we don’t want to see,” Beshear said at his weekly news conference.
“It reduces or eliminates litigation, and it creates a more fair process, not one where people bid against each other and only then the big companies can be a part of it,” the governor said. “But one that provides at least a chance for everyone who can meet the criteria.”
The state initially will issue 48 medical cannabis dispensary licenses, divided among 11 regions. The goal is to ensure the shortest possible drive times for Kentuckians with qualifying health conditions, said Sam Flynn, executive director of the medical cannabis program.
Each region will be allocated at least four dispensary licenses, and counties will be limited to one dispensary with the exception of those that are home to Louisville and Lexington, which can have two licenses, Flynn said.
Limited numbers of cultivator and processor licenses will be issued.
Caps on licenses are meant to avoid flooding the market with medicinal cannabis products and exceed demand, which would hurt businesses and patients, the governor said.
“You can see this is not about having a dispensary on every corner,” Beshear said. “It is a limited program that we can monitor and fulfill the promise we made of doing this safely, but also having access in each region for people that do qualify.”
The program can be expanded with more businesses in the future depending on demand and whether more qualifying medical conditions are added.
“This is likely the minimum that you will see on the program moving forward,” Beshear said. “But again, you can always scale up. Scaling back hurts businesses, hurts people and hurts access.”
"We don’t start huge. We start with a manageable program that, yes, can grow,” he added.
On Wednesday the Democratic governor signed legislation moving up the timeline for licensing cannabis businesses by six months, with the window for applications running from July 1 through the end of August. The change makes it likely that at least limited supplies will be available in January when they become legal, Beshear said.
Medical marijuana supporters overcame years of setbacks in Kentucky when lawmakers passed the measure last year legalizing medical cannabis for people suffering from a range of debilitating illnesses, including cancer, multiple sclerosis, chronic pain, epilepsy, chronic nausea and post-traumatic stress disorder.
The governor has advocated for adding more conditions to the qualifying list, but the bill he signed Wednesday did not do so.
Local governments and schools can decide not to participate in the state program.
99
« Last post by orthene on April 12, 2024, 11:34:20 PM »
https://www.msn.com/en-us/health/other/cannabis-use-is-linked-to-a-lower-likelihood-of-experiencing-subjective-cognitive-decline/ar-BB1l7xlA?ocid=msedgdhp&pc=U531&cvid=aa9b8763821044ffa6b259cc3d6e82bf&ei=63In a new study published inCurrent Alzheimer Research, scientists have found that non-medical cannabis use is linked to a lower likelihood of experiencing subjective cognitive decline, a condition characterized by self-reported memory loss or confusion. This intriguing discovery sheds light on the complex relationship between cannabis use and cognitive health, particularly among middle-aged and older adults in the United States.
With the aging population and the rising prevalence of cognitive impairments, understanding the factors that can influence cognitive health is more crucial than ever. Subjective cognitive decline has been recognized as a potential early warning sign for more severe cognitive disorders, including dementia. At the same time, cannabis use is becoming more common, especially among older adults, prompting scientists to explore its potential impacts on cognitive function.
“There has been increasing attention about cannabis because more states continue to expand legalization, and subsequently more adults also have begun experimenting with the substance,” said study author Roger Wong, an assistant professor in the Norton College of Medicine at SUNY Upstate Medical University.
“I had noticed that most research on cannabis was only focusing on how frequency of cannabis use is associated with cognition. Thus, I expanded on prior research by examining how cognitive decline may result from different facets of cannabis use, such as reason (medical or non-medical), frequency (0-30 days/month), and method (smoke, vape, eat, etc.).”
For their study, the researchers analyzed data from the 2021 Behavioral Risk Factor Surveillance System (BRFSS), focusing on U.S. adults aged 45 and older. The BRFSS is a cross-sectional survey designed to collect information on health-related risk behaviors, chronic health conditions, and use of preventive services among American adults.
Specifically, this study zeroed in on respondents from Washington D.C. and 14 states that included the BRFSS cognitive decline module in their survey, resulting in an unweighted sample of 4,744 participants with valid responses on subjective cognitive decline.
Subjective cognitive decline, the study’s dependent variable, was assessed using a specific question from the BRFSS cognitive decline module: “During the past 12 months, have you experienced confusion or memory loss that is happening more often or is getting worse?”
Individuals who used cannabis for non-medical reasons reported significantly reduced odds of experiencing subjective cognitive decline compared to those who did not use cannabis. This suggests that non-medical cannabis use, as opposed to medical or mixed-use, might have a protective association against the self-perception of cognitive decline.
Interestingly, when examining the frequency of cannabis use and the methods of consumption (smoking, eating, drinking, vaporizing, or dabbing), the study found no significant association with subjective cognitive decline after adjusting for a comprehensive set of covariates. This finding indicates that the reason behind cannabis use (medical vs. non-medical) may be more pivotal in its relationship with subjective cognitive health than the quantity of use or the specific method of consumption.
Further analysis through multiple logistic regression models highlighted that, after controlling for various demographic, health, and substance use factors, non-medical cannabis use was associated with a 96% decrease in the odds of reporting subjective cognitive decline. This relationship remained consistent across different models, even after adjusting for a wide range of potential confounders.
“Non-medical cannabis use, such as for recreational purposes, may decrease cognitive decline, which is often a precursor to future diagnosis of dementia, which currently has no definitive prevention approach, no cure, and very limited treatment options,” Wong told PsyPost.
But the study has some limitations to consider. It didn’t account for potential geographical variations in cannabis legislation and use within the United States. The reliance on self-reported data, especially concerning cannabis use and cognitive decline, may introduce bias. Furthermore, the study’s focus on adults 45 years and older leaves unanswered questions regarding the impact of cannabis on younger populations.
Looking ahead, the researchers emphasize the need for further studies to explore the mechanisms underlying the observed association between non-medical cannabis use and reduced odds of subjective cognitive decline.
“We analyzed the U.S. CDC BRFSS (Behavioral Risk Factor Surveillance System) data, which has been collected annually since 1984,” Wong explained. “We specifically only analyzed the 2021 data since it contained the three cannabis measures. Thus, although our findings may suggest cannabis may be beneficial for cognition, it is imperative for future research to examine the relationship between long-term cannabis use and cognition. This is not feasible right now because cannabis remains illegal federally.
“Non-medical cannabis typically contains higher concentrations of a compound called THC, whereas medical cannabis typically contains higher concentrations of a compound called CBD,” the researcher added. “It is theorized that non-medical cannabis is being used for stress relief and improve sleep, which my prior research00009-0/fulltext) has found sleep disturbances to be a major risk factor for dementia.”
The study, “Association Between Cannabis Use and Subjective Cognitive Decline: Findings from the Behavioral Risk Factor Surveillance System (BRFSS),” was authored by Zhi Chen and Roger Wong.
100
« Last post by orthene on April 11, 2024, 11:03:57 PM »
https://www.msn.com/en-us/health/other/fda-chief-sees-no-reason-for-delay-in-cannabis-rescheduling/ar-BB1ltaBK?ocid=msedgntp&pc=U531&cvid=dc69f2cbe83f4125afa69fda8bcd2d05&ei=13Amid an ongoing review by the Drug Enforcement Administration (DEA) to reschedule marijuana from a high-risk to a low-risk category, the head of the U.S. Food and Drug Administration (FDA), Robert Califf, said Thursday that there's "no reason" for the DEA to delay its decision.
In August, the U.S. Department of Health and Human Services (HHS) wrote a letter to the DEA recommending cannabis be reclassified from a Schedule I to a Schedule III drug under the Controlled Substances Act (CSA) based on the FDA's findings.
In January, the DEA confirmed the ongoing review. A favorable decision will see marijuana moving to Schedule III, a low-risk category for medications like Tylenol and ketamine, from its current category in Schedule I, which includes dangerous drugs like heroin and LSD.
"There's no reason for DEA to delay. They have to take into account all the regulations that are in play," FDA commissioner Califf said during a hearing before the House Oversight and Accountability Committee on Thursday.
Meanwhile, rescheduling opponent Rep. Pete Sessions (R-TX) argued that the FDA's assessment of cannabis that led to the HHS recommendation was not based on "scientific facts or realities of how marijuana has been abused and used in our country today."
"Let me remind you that a Schedule III does not put marijuana on the market in the United States," Califf said in response, according to industry publication Marijuana Moment. "With all due respect, I think [cannabis] is differentiable from heroin and, I think, cigarettes."
Pages: 1 ... 6 7 8 9 [10]
|
Recent Posts